imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. efekt imatinib na wynik przeszczepienia szpiku kostnego nie jest określona. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. doświadczenie z imatinibom u pacjentów z mds/jest msy, związanych z pdgfr genów permutacji-bardzo ograniczony. brak kontrolowanych badań wykazują kliniczną korzyść lub zwiększone tempo dla tych chorób.
ancotil 10 mg/ml roztwór do infuzji
bausch health ireland ltd. - flucitosinum - roztwór do infuzji - 10 mg/ml
depakine 288,2 mg/5 ml syrop
sanofi winthrop industrie - natrii valproas - syrop - 288,2 mg/5 ml
diane - 35 2 mg + 0,035 mg tabletki powlekane
bayer ag - cyproteroni acetas + ethinylestradiolum - tabletki powlekane - 2 mg + 0,035 mg
marvelon 0,15 mg + 0,03 mg tabletki
organon polska sp. z o.o. - desogestrelum + ethinylestradiolum - tabletki - 0,15 mg + 0,03 mg
mercilon 0,15 mg + 0,02 mg tabletki
organon polska sp. z o.o. - desogestrelum + ethinylestradiolum - tabletki - 0,15 mg + 0,02 mg
microgynon 21 30 mcg + 150 mcg tabletki powlekane
bayer ag - ethinylestradiolum + levonorgestrelum - tabletki powlekane - 30 mcg + 150 mcg
depakine 400 mg (400 mg/4 ml) proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
sanofi winthrop industrie - natrii valproas - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań - 400 mg (400 mg/4 ml)
cyprodiol 2 mg + 0,035 mg tabletki powlekane
sun-farm sp. z o.o. - cyproteroni acetas + ethinylestradiolum - tabletki powlekane - 2 mg + 0,035 mg
logest 0,075 mg + 0,02 mg tabletki powlekane
bayer ag - gestodenum + ethinylestradiolum - tabletki powlekane - 0,075 mg + 0,02 mg